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1. Introduction 
 
1.1 Colorectal cancer: epidemiology and genetic and molecular characterization 
 
Colorectal cancer (CRC) is the second main cause of cancer death, leading to over 700,000 
deaths annually in worldwide and is the second most diagnosed tumour (accounting for 
16% and 13% of newly diagnosed cancers in men and women, respectively) and principal 
cause of death in Italy (11%) [1, 2]. 
It is currently known that the risk of developing CRC is not only influenced by hereditary 
predisposition or medical conditions (i.e. chronic inflammatory bowel disease and type 2 
diabetes), but is also strongly associated with a western lifestyle which can increase the 
risk of developing CRC. Indeed, the increase in incidence is associated with risk factors 
among which smoking, diet (with an excess of body weight), and alcohol [3, 4]. 
Given the multiplicity of factors underling its development, we can epidemiologically 
distinguish three types of CRC based on origin and expression: a sporadic form (65%), a 
familial type (30%) and a hereditary type (<5%); the latter can in turn be associated or not 
with familial adenomatous polyposis (FAP or HNPCC, respectively) [3, 5]. 
General principles of current CRC treatment include radical surgical resection and, in more 
advanced stages, surgery can be preceded or followed by chemotherapy (neoadjuvant 
therapy and adjuvant therapy, respectively) and radiotherapy. CRC chemotherapy 
treatment is based on the use of fluoropyrimidine for intravenous infusion (5-fluorouracil 
(5FU)) or for oral use (capecitabine), variously associated in doublets or triplets to 
irinotecan and oxaliplatin [6-8].  
CRC is a specific multifactorial pathology, different from individual to individual; 
alterations of the genetic and epigenetic background, indeed, are specific to each patient 
and to predict the tumour progression steps, different classification methods are currently 
used [9]. Specifically, three main pathways of CRC development and progression have 
been defined: they include aberrations in global genomic status [Chromosomal INstability 
(CIN) status and MicroSatellite Instability (MSI) status] and epigenomic status [CpG 
Island Methylator Phenotype (CIMP) status]. These mechanisms play a significant role in 
determining characteristics of tumour [10]. CIN, MSI and CIMP status, indeed, are 
characterized by specific pathological precursors which are found in three fundamental 
categories of genes: tumour suppressor genes [e.g. Adenomatous polyposis coli (APC), and 
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tumour protein 53 (TP53)], protoncogenes (e.g. KRAS, NRAS), and DNA repair genes [e.g. 
mismatch repair (MMR) and mutY Homolog (MUTYH)] [11]. 
APC gene mutations were one of the earliest genetic events identified in the development 
of CRC and indicate a pivotal role for the WiNgless-Type MMTV integration site family 
member (Wnt) pathway in CRC tumorigenesis [12]. APC is considered a tumor-suppressor 
in CRC and it is dysregulated at both the germline and somatic level (APC mutations 
occurs in 80% of sporadic colorectal tumours and loss of heterozygosity (LOH) is reported 
in 30%–40% of CRC patients) [13]. 
Somatic mutations in the TP53 gene are one of the most frequent alterations in human 
cancers; in particular, in CRC, the frequency of TP53 mutations is around 45%. It is 
actually known that different mutations in TP53 correlate with different prognosis, 
moreover patients with TP53 mutations could derive more benefit from 5FU-based 
chemotherapy [14].  
Phosphatidylinositol-3-Kinase (PI3K) signalling is deregulated in CRC through a variety 
of mechanisms, including loss of Phosphatase and tensin homolog deleted on chromosome 
10 (PTEN); loss of PTEN expression occurs in 30% of sporadic cases, and is associated 
with lack of response to Epidermidal Growth Factor Receptor (EGFR) inhibitors 
(cetuximab) [15]. Sartore-Bianchi and colleagues demonstrated that combined profiling of 
KRAS, PI3K, and PTEN could identify patients with metastatic CRC (up to 70%) of who 
would fail to benefit from anti-EGFR antibodies [16]. 
The KRAS proto-oncogene encodes for a guanosine triphosphate (GTP)/guanosine 
diphosphate that exerts its role in Mitogen-Activated Protein Kinase (MAPK) pathway 
downstream of the EGFR. Mutations in KRAS may occur early in the development of pre-
cancerous adenomas in the colon and rectum and are detected in 30-40% of CRC cases 
[17]. KRAS plays a critical role in CRC treatments, although is not a significant prognostic 
factor. Randomised clinical trials demonstrated that, for patients with KRAS wild-type, the 
addition of cetuximab to standard chemotherapy improves best overall response rate 
(ORR), progression free survival (PFS) and overall survival (OS) compared with those 
patients receiving chemotherapy alone [18].  
Deficiencies in the MMR system lead to a hypermutator phenotype; the insertion or 
deletion of repetition units drive the mutation of genes involved in apoptosis regulation or 
implicated in cellular regulation of growth, such as BCL2-associated X protein (BAX), 
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transforming growth factor beta receptor II (TGFβRII), or insulin-like growth factor II 
receptor (IGFIIR), respectively [19, 20].  
 
 
1.2 Druggable targets in CRC treatment: MAPK and PI3K pathways 
 
The RAS-MAPK and PI3K signalling pathways play a central role in tumorigenesis, and in 
particular in CRC; for this reason, the analysis of mutations or other molecular aberrations 
in these pathways could have numerous clinical implications [21].  Extensive cross-talk 
interconnecting the two pathways and occurring at different hubs of signalling cascades 
through “vertical” and “lateral” feedback loops [22], form the bases for therapeutic 
strategies that exploit the single or combined action of molecular target inhibitors 
downregulating the two molecular pathways [23]. 
 
1.2.1 MAPK signalling pathways 
 
The MAPK pathways incorporate proline-directed and protein-serine/threonine kinases, 
which regulate numerous processes in both normal and cancer cells, such as: 
embryogenesis, cell differentiation, cell proliferation, and cell death [24].  
Different MAPK cascades have been identified: extracellular signal-regulated kinase 
(ERK) 1 and 2, c-Jun N-terminal kinase (JNK), p38, and ERK5; nevertheless, the ERK1/2 
cascade was the first identified and most extensively characterized MAPK pathway [25, 
26]. 
The signalling cascade is composed of a set of three evolutionarily conserved, sequentially 
acting kinases: a MAPK, a MAPK kinase (MAPKK), and a MAPKK kinase (MAPKKK). 
The MAPKKKs, could be activated through phosphorylation of tyrosine kinase receptors 
(RTKs) and/or as a result of their interaction with a small GTP-binding protein of the 
RAS/Rho family in response to extracellular stimuli [27, 28].   
The activation of RTKs is transmitted to the small GTPase RAS, which is activated mainly 
at the plasma membranes. Three genes encode four different RAS proteins: HRAS, NRAS, 
KRAS-4A and KRAS-4B, the latter two being alternative splice variants of the KRAS gene, 
and differ according to the capability which they activate the transduction cascade: KRAS, 
indeed, activates with greater efficacy RAF/MEK/ERK signalling cascade, while HRAS 
more effectively activates PI3K/mTOR pathway [29, 30]. Activated RAS, recruits RAF to 
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plasma membrane leading to its activation through phosphorylation and homo- and hetero-
dimerization between BRAF and CRAF [31]. RAF activates, in turn, MEK1 and MEK2 
(MEK1/2) through phosphorylation of two Ser residues in the activation loop, allowing for 
the activation of ERK1/2, phosphorylated in turn by MEK1/2 [32]. Once activated, ERK 
can regulate numerous proteins in the cell: it can directly or indirectly phosphorylate and 
activate many transcription factors, such as c-Jun and cAMP (Adenosine 3'5' Cyclic 
Monophosphate) Response Element-Binding Protein (CREB) through the phosphorylation 
of 90 kDa ribosomal S6 kinase (p90rsk), respectively [33].  
Target-based therapies are focused on developing RAS/RAF/MEK signalling pathways 
inhibitors and several MEK1/2 and RAF inhibitors have been tested clinically or are 
currently in clinical trial for CRC and other cancers [34]. KRAS and BRAF mutations 
should be able to predict sensitivity to RAF-targeted agents, but CRC resistance to BRAF 
inhibition has been demonstrated both preclinically and clinically and has been attributed 
to rebound activation of EGFR at the cell membrane. Phase III clinical trials demonstrated 
that BRAF and KRAS mutations were negative predictors of benefit to cetuximab and 
panitumumab [35]; in spite of this, in patients with PI3K wild-type/KRAS mutant CRC, the 
addition of a PI3K inhibitor (such as BKM120) may overcome cetuximab resistance [36].  
 
1.2.2 PI3K/mTOR signalling pathways 
 
The PI3K pathway plays a central role in cell growth, proliferation, survival, and 
angiogenesis in both normal and malignant cells and thus is an attractive target for targeted 
molecular therapy [37].  
PI3Ks family includes three different classes of kinase: I, II, III; each class has different 
characteristics, both in the molecular structure and in substrate specificity. Following 
binding to membrane receptors, class I PI3K phosphorylate substrate phosphatidyl-inositol 
4,5 bisphosphate (PIP2) to phosphatidylinositol 3,4,5 triphosphate (PIP3). PIP3 recruits’ 
proteins containing the pleckstrin homology domain (PH) to the cytoplasmic membrane, 
including the protein kinase dependent phosphoinositide (PDK1) and the serine/threonine 
protein kinase B (PKB, also known as AKT) [38]. Full activation of AKT is a multistep 
process consisting of the phosphorylation of two different residues, Thr308 and Ser473, via 
PDK1 and PDK2, respectively [39]. Given its pivotal role in cell proliferation and survival 
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through phosphorylation of different substrates, overexpression of activated AKT isoforms 
can transform cells and AKT alteration is common in different human cancer [40, 41], 
including CRC [42]. 
The mammalian target of rapamycin (mTOR) is a critical downstream regulator of the 
PI3K pathway, playing a fundamental role in the regulation of growth, proliferation, and 
cellular metabolism [43, 44]. mTOR can act as a substrate and effector of the AKT 
pathway: indeed, AKT indirectly activates mTORC1 by direct phosphorylation of the 
tumour suppressor Tuberous Sclerosis Complexes (TSC) 2 on Ser939 and Thr1462, but 
evidence show that mTORC2, can also phosphorylate directly AKT at Ser473 [45]. mTOR 
is a serine/threonine kinase that exerts its function through two functionally and 
structurally distinct multi-component complexes, mTORC1 and mTORC2 [46].  mTORC1 
is composed by the core proteins mTOR (that can bind other proteins in a species- and 
condition-specific manner, such as: Proline-Rich AKT Substrate 40 (PRAS40), DEP 
domain-containing mTOR interacting protein (DEPTOR), GRp58, Tel2-interacting protein 
1 (Tti1)- Telomere maintenance 2 (Tel2), Rac1, Regulatory-associated protein of mTOR 
(Raptor) and mLST8 [47].   
mTORC2 complex includes the core proteins mTOR, Rapamycin insensitive companion of 
mTOR (Rictor), and mammalian Lethal with Sec13 protein 8 (mLST8), as well as various 
associated proteins, Proline-Rich Protein (PRR) 5, Heat shock protein (Hsp) 70, DEPTOR, 
GRp58, Tti1-Tel2, Rac1, mammalian Stress-activated protein kinase Interacting protein 
(mSIN) 1 and Protein observed with RICTOR (Protor) [47]. 
mTORC1 is activated by growth factors, amino acids, and energy levels and regulates 
different processes, such as growth, proliferation, biosynthesis of macromolecules, and 
angiogenesis, by regulating p70 ribosomal protein S6 Kinase 1 (p70S6K1) and Elongation 
Initiation Factor (EIF)-4E Binding Protein 1 (4E-BP1) [46]. mTORC2 is primarily 
responsive to growth factors and controls cell structure, cytoskeletal reorganization, and 
survival by activating Serum and Glucocorticoid Kinase (SGK), AKT, and Protein-Kinase 
C (PKC) [46]. 
Recently, preclinical and clinical studies for the treatment of CRC revealed the efficacy of 
targeting PI3K signalling pathway, and in particular dual PI3K/mTOR inhibitors, that 
overcome the feedback loop activation of PI3K [48]. Molecular inhibitors, such as 
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GSK2126458, DS 7423, XL765 e NVP-BEZ235 are currently being tested in clinical 
trials, although dual inhibition could lead to substantial toxicity [49].  
 
 
1.3 The PTEN tumour suppressor 
 
The signal transduction pathway mediated by the PI3K proto-oncogene is regulated 
negatively by PTEN. The PTEN tumour suppressor is the main negative regulator of the 
PI3K pathway and a common target for inactivation in sporadic cancers [50]. Somatic 
mutations, transcriptional silencing, deletions or protein instability in PTEN occur in 
different human tumours, and PTEN loss of function is found in 9-30% of CRC patients 
[51].  
PTEN levels and/or function can be regulated through multiple mechanisms, including 
transcriptional and post-transcriptional regulation, subcellular localization, post-
translational modifications, and proteins interaction [52, 53]. 
 
1.3.1 PTEN regulation 
 
PTEN gene is negatively and positively regulated by different transcription factors. 
Negative regulators can directly (such as c-JUN) and indirectly (such as nuclear factor 
kappa B (NF-KB)) inactivate PTEN expression, while positive regulators include different 
protein such as TP53 and early growth response protein 1 (EGR-1) [52]. 
microRNAs (miRNAs) are the principal regulators of PTEN abundance at the post-
transcriptional level. Different miRNAs include those derived from miRNA precursors 
containing a single hairpin structure (e.g.  miR-21, miR-22 and miR-205), as well as those 
with a polycistronic structure (e.g. mir-17-92, mir-106b-25, mir-367-302b, and mir-221-
222); they can play a role as a tumour suppressor or oncogenes leading to increased or 
decreased PTEN levels, respectively [54].   
Numerous post-translational modifications (such as ubiquitination, acetylation, 
sumoylation, and phosphorylation) modify the proprieties of the PTEN tumour suppressor 
and impact on PTEN localization in the cell. 
Monoubiquitination or ubiquitination of specific residues (such as Lys13 and Lys289) are 
involved in PTEN shuttling and nuclear import, while PTEN polyubiquitination leads to 
PTEN cytoplasmic retention and degradation. Although the acetylation of Lys402 does not 
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involve a change in the intracellular localization of PTEN, this modification enhances the 
interaction of PTEN with PDZ-domain proteins. While sumoylation is essential to PTEN 
tumour suppressive functions, by increasing the anchorage to the plasma membrane, the 
phosphorylation in C-terminal cluster of Ser and Thr maintains PTEN in a closed 
conformation, reducing its phosphatase activity and membrane localization. PTEN C-
terminal tail is phosphorylated by different kinases, Casein Kinase (CK) 2, Glycogen 
synthase kinase 3 beta (GSK3), RAK, protein interacting with carboxyl terminus 1 
(PICT-1) and Rho-associated kinase (ROCK) [55, 56].  
 
1.3.2 PTEN functions 
 
Besides PTEN main role as a negative regulator of the PI3K pathway, different functions 
associated with this tumour suppressor are currently known.  
PTEN is involved in the control of metabolic pathways: indeed, it regulates different 
processes such as glucose uptake, by controlling the membrane expression of glucose 
transporter type 1 (GLUT1) and/or the levels of gluconeogenesis through inhibition of 
forkhead box O (FOXO) 1 [53].  
PTEN is also involved in the regulation of cell motility and polarity; such PTEN role in 
migration is PI3K pathway-independent: indeed, PTEN can inhibit glioma cell migration 
independently of its phosphatase activity [57].  
The absence of nuclear PTEN is a prognostic indicator in different aggressive cancers 
including CRC [58]. The importance of PTEN in the nucleus is associated with its role in 
controlling cell cycle progression, DNA repair and genomic stability [53, 59]. 
Furthermore, recent evidence highlight the role of PTEN in regulating the tumour 
microenvironment (TME). Experiment in mice demonstrate that deletion of PTEN in 
fibroblasts creates a tumour-permissive stroma in mammary gland tumours, with 
recruitment of innate immunity cells, remodelling of the ECM and tumour vasculature, and 
increased malignancy of tumours [60]. PTEN's regulation of the tumour microenvironment 
is also related to the modulation of cytokines in the microenvironment itself; indeed, a 
relationship between PTEN-loss and Interleukin (IL)-8 upregulation is known in prostate 
carcinoma and glioblastoma [61, 62]. Numerous studies show the active contribution of 
PTEN to the regulation of angiogenesis at different levels. PTEN loss in cancer cells leads 
to increased Vascular Endothelial Growth Factor (VEGF) expression, due to the 
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upregulation of Hypoxia-Inducible Factor (HIF) 1, while PTEN transfection in multiple 
myeloma cell line results in a decreased mRNA and protein expression of Matrix 
Metallopeptidase (MMP)2, MMP9 and FAK (Focal Adhesion Kinase), leading to 
decreased cell migration [63]. 
Recent studies highlight the therapeutic potential of agents that target Programmed death-1 
(PD-1) or its ligand Programmed death ligand-1 (PD-L1) that have been identified as a 
factors associated with poor prognosis in different types of cancer [64]. Loss of the tumour 
suppressor PTEN may induce PD-L1 overexpression, thus inducing immunoresistance in 
CRC [65].  
 
 
 
Figure 1. PTEN regulation and function. 1. Activation and/or inhibition of PTEN mRNA transcription; 2. 
post-transcriptionally regulation of PTEN mRNA by miRNAs; Post-translational modifications: 3. 
phosphorylation of the PTEN C-terminal tail; 4. poly- and mono-ubiquitination of PTEN, NEDD4-1-
mediated; 5. deubiquitination of PTEN in the nucleus and nuclear exclusion; 6. PIP3 dephosphorylation and 
suppression of PI3K pathways; 7. regulation of the cell cycle PTEN-mediated, 8. PTEN association with 
centromeres in the nucleus for chromosome stability maintenance.  (Modified from Zhang S., and Yu D. 
2010 [66]) 
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1.4 TME 
 
TME is fundamental in different steps of tumour progression (Figure 2); indeed, tumour is 
not composed only by a mass of transformed cells, but also by different “genetically 
normal” host-derived cell types, and cancer development cannot be dissociated from its 
local microenvironment. Extracellular matrix (ECM), immune and inflammatory cells, and 
fibroblasts are the main components of TME [67]. 
ECM is composed by a complex network of macromolecules such as proteins, 
glycoproteins, proteoglycans, and polysaccharides that may serve to block or facilitate, not 
only cell migration, but also free diffusion of cytokines, growth factors, and hormones 
secreted by stromal and tumour cells; its dysregulation is one of the hallmarks of cancers 
and the enzymes involved in ECM remodelling are and produced by immune cells and 
cancer-associated fibroblasts (CAFs) [68]. 
Immunity cells and their reciprocal interaction with tumour cells are the principal elements 
involved in TME inflammatory process. Solid tumors are commonly infiltrated by immune 
cells, belonging to both adaptive (e.g. T cells, B cells, natural killer (NK) cells) and innate 
immunity (e.g macrophages, dendritic cells (DCs), neutrophils, eosinophiles, basophiles 
and mast cells) [69]. Macrophages are a major component of innate immune cells and 
particular interest has been attribuited to tumour-associated macrophages (TAM) [70]; 
indeed, TAMs accumulation is associated with poor clinical outcome.  
CAFs are the major components of cancer stroma, their crucial role is associated with 
progression, growth and invasion. CAFs may derived from both normal fibroblast (through 
genetic alteration that leads to a constitutively activated phenotype) and epithelial cells 
(through epitelial-mesenchimal transition (EMT)); different markers of CAFs were 
actually identified including alpha smooth muscle actin (SMA), fibroblast activation 
protein (FAP), Thy-1, desmin, and S100A4 protein [71]. It’s actually known that fibroblast 
activation in CRC patients correlates with a high risk to develop metastases or recurrence 
and to have an aggressive disease progression [72]. 
The various cells that compose TME can modulate treatment response and are therefore 
potential candidates for therapeutic intervention. Currently, clinical studies that target TME 
components are in progress and different elements of TME are targeted; among them, 
siltuximab and ruxolitinib, that act by inhibiting IL-6 and JAK, respectively, block 
inflammatory pathway activation, whereas bevacizumab inhibits VEGF and is a mainstay 
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in the therapy of CRC [73]. Indeed, In KRAS wild type and mutant CRC, antibody 
treatment (such as bevacizumab) plus FOLFOX-4 show 9.3 and 8.7 months of PFS, 
respectively [74]. 
 
 
 
Figure 2. Contribution of stromal cells to the Hallmarks of cancer [75] 
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2.  Aim of the study 
 
Our group has recently demonstrated that PTEN plays a crucial role in determining the 
functional outcome of combined MAPK/PI3K inhibition in a panel human cancer cell lines 
of different histological origin, including CRC. These studies show that growth inhibitory 
synergism with combined MAPK/mTOR inhibition is almost invariably observed in cells 
with PTEN-loss, but not in PTEN-competent tumour cells [76]. Identification of the 
precise mechanisms of drug action in relationship to molecular disease drivers is crucial to 
the successful development of new therapeutic strategies and recently high-throughput 
molecular analysis is being used to identify putative biomarkers to provide personalized 
cancer therapy. However, such analysis is usually focused on tumour cell-autonomous 
molecular determinants of sensitivity to drug treatment and overlooks microenvironmental 
interactions. 
The aim of the study is to investigate how PTEN expression/function in CRC cells 
modulates the response to signalling inhibitors in the context of complex 
microenvironmental interactions. 
To this purpose, we have investigated the potential role of stroma in response to 
"horizontal" combinations of agents targeting MEK and PI3K/mTOR signalling in CRC 
cells differing for PTEN status in different culture conditions, the alternative responses 
generated by different elements of stroma-endothelial microenvironment, and finally the 
potential role of PTEN in regulating responses to microenvironmental cues. 
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3. Materials and Methods 
 
3.1 Cell cultures 
 
X-MAN™ HCT116 and HCT116 PTEN-/- were generated by Horizon from homozygous 
knock-out of PTEN by deleting exon 5 which encodes the active site of the protein in the 
CRC cell line HCT116 (Horizon Discover www.horizondiscovery.com). Cell lines were 
routinely maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, and antibiotics (Pen/Strep) in a humidified atmosphere with 5% 
CO2 at 37 °C. Fibroblast cell line HFF (human foreskin fibroblasts) GFP-labeled, HF and 
BJ were kindly provided by Dr. Maurizio Fanciulli. EA.hy926 was obtained from the 
American Type Culture Collection (ATCC). Fibroblast and endothelial cells were routinely 
maintained in DMEM medium supplemented with 15% fetal bovine serum (FBS), 2 mM 
L-glutamine, and antibiotics (Pen/Strep) in a humidified atmosphere with 5% CO2 at 37 
°C. 
Cell culture reagents were purchased from Euroclone and Invitrogen (Milan, Italy). 
To obtain stromal cells conditioned medium (CM), HFF, BJ, HF and EA.hy926 cells were 
seeded and the media was replaced by serum-free medium (SFM) after 24 hours from 
plating; CM was collected after 72 hours. 
 
 
3.2 Drug treatments 
 
Trametinib (GSK1120212) was kindly provided by GlaxoSmithKline (Brentford, 
Middlesex, UK). Gedatolisib (PF05212384) and alpelisib (BYL719) were kindly provided 
from Selleck Chemicals (Huston, TX, USA). MK-2206 was obtained from by Merck and 
Co. (Kenilworth, NJ, USA). Trametinib, gedatolisib, alpelisib, and MK-2206 were 
dissolved in DMSO as a 1 mM (trametinib, gedatolisib and MK-2206) and 5mM (alpelisib) 
stock solution, and stored at -20°C or -80°C. Everolimus (RAD001) was obtained from 
Novartis Pharma (Basel, Switzerland) and was dissolved in 100% ethanol as a 10 mM 
stock solution and stored at -20°C.  
The final concentration of drugs was obtained by dilution with culture medium. 
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3.3 Cell viability assay 
 
Cell proliferation was evaluated by direct cell counting or Crystal Violet assay. 
For cell counting, Thoma chamber was used. Effects on cell growth in response to different 
treatments were monitored by Crystal Violet assay. For Crystal Violet assay, a fixed 
number of tumour cells were dispensed into 24-wells (NEST Biotechnology), and the 
following day cells were treated at indicated concentrations of drugs. After 72 hours of 
treatment, the cells were washed with PBS, fixed with 4% formaldehyde for 10 minutes 
and then stained with 0.1% Crystal Violet for 40 minutes, at room temperature. Excess 
stain was removed with water and the plates were dried. Crystal violet stain was extracted 
with 95% acetic acid and the absorbance was measured at 570 nm. 
The dose of drug that causes 50% of cell growth inhibition (IC50 value) was calculated 
according to the Chou-Talalay method using the Calcusyn software (Biosoft, Cambridge, 
United Kingdom). 
 
 
3.4 CRC-fibroblast co-culture 
 
HFF fibroblasts were used to develop a CRC/stroma co-culture model, in order to 
investigate the influence of stromal cells on CRC cell growth and drug sensitivity in 
correlation with the presence/absence of PTEN.  
X-MAN™ HCT116 and HCT116 PTEN-/- cells and fibroblast cells GFP-labeled were 
seeded alone or with a ratio of 1:1 in plates 35 mm, in RPMI 1640 supplemented with with 
10% FBS, 2 mM L-glutamine, and antibiotics (Pen/Strep) in a humidified atmosphere with 
5% CO2 at 37 °C. After 24 h the medium was replaced with SFM containing different drug 
concentration alone or in combination. After 72 h cells were harvested and resuspended in 
ice-cold RPMI 1640 10% FBS. The total amount of cells was counted in the Thoma 
chamber and the percentage of CRC cells and fibroblast cells in co-culture were analysed 
by flow cytometry analysis that allows to differentiate between HFF cellular populations, 
fluorescently labeled in comparison to unlabeled X-man cells. 
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3.5 Statistical analysis 
 
The Mann-Whitney U test was used for comparing quantitative variables.  Results with 
two-tailed P values <0.05 were judged to be statistically significant. Synergism, additivity, 
and antagonism were assessed by isobologram analysis with a fixed-ratio experimental 
design using the Chou-Talalay method [77]. Results were analysed with the Calcusyn 
software (Biosoft, Cambridge, United Kingdom) and combination indexes (CI) were 
appropriately derived. By this method, an average CI at the ED50, ED75, and ED90 < 1 
indicates synergism, = 1 indicates additivity, and > 1 indicates antagonism, respectively.  
 
 
3.6 Immunofluorescence 
 
Cells were seeded on on 22x22 mm coverslips and the media was replaced by SFM and 
HFF CM after 24 hours from plating. After 24 hours from the replaced medium the grown 
cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min, 
permeabilized in PBS containing 0.5% Triton X-100 for 5 min, and blocked with PBS 
containing 5% Bovine Serum Albumin (BSA) and 0.3% of Triton X-100 for 90 min. 
Coverslips were incubated overnight with primary antibodies in 1% BSA, 0.3% Triton X-
100 in PBS. Coverslips were then washed three times in PBS and then incubated with one 
of the following secondary antibodies for 1 h at a dilution of 1:200: goat antirabbit Alexa 
Fluor 488 (A11034, Invitrogen) and goat antimouse Alexa Fluor 594 (A11032, Invitrogen). 
After washing, the nuclei were counterstained with DAPI. Cells were then washed twice 
with PBS and observed under Zeiss Axiovert 200 M fluorescence microscope. Specific 
fields were photographed with a digital camera equipped with Zeiss Axiovision acquisition 
software. 
 
 
3.7 Western blot analysis 
 
Whole cell extracts were obtained by Chaps Cell Extract buffer, containing 50 mM 
Pipes/Hcl (pH 6.5), 2 mM EDTA, 0.1% Chaps, 20 g/ml Leupeptin, 10 g/ml Pepstatin A, 
10 g/ml Aprotinin, 5mM 1,4-Ditiotreitolo (DTT). Assay sample for protein concentration 
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used was Bradford (Protein Assay Dye Reagent Concentrate, Bio-Rad). An amount of total 
cell lysate was fractionated by SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membrane (Amersham, Arlington Heights, USA). Membranes were probed 
with the following primary antibody: phosphorylated (Ser380/382/383) and total PTEN, 
phosphorylated (Thr389) p-p70S6K, phosphorylated (Thr202/Tyr204) ERK1/2, mTOR, 
RAPTOR, PRAS40 and Rictor, phosphorylated (Thr37/46) p-4E-BP1 (from Cell Signaling 
Technology Inc. Beverly, USA). Signal was detected using peroxidase-conjugated anti-
mouse or anti-rabbit secondary antibodies (Jackson Immunoresearch Labs, Inc., Baltimore, 
USA). The enhanced chemi-luminescence (ECL) system (Amersham) was used for 
detection and image detection was performed with UVITEC Alliance 4.7 system 
(Cambridge, UK). To control the amount of proteins transferred to nitrocellulose 
membrane β-actin and GAPDH were used and detected by anti β-actin mAb (clone AC-15, 
Sigma, St. Louis, USA) and by anti GAPDH (Abcam, Cambridge, MA, USA) respectively. 
 
 
3.8 Immunoprecipitation  
 
Chip-Grade Protein A/G Magnetic Beads (Thermo Fisher Scientific, Rochester, NY, USA) 
were incubate with 2 g of FRAP (Santa Cruz Biotechnology, Santa Cruz, CA) over night 
at 4 °C. Precleared beads were than incubated over night at 4 °C with 1 g of protein. The 
immunoprecipitates were collected and after 2 wash in CHAPS buffer re-suspended in 35 
µl of the same buffer and Ladder buffer 1X. The immune complexes and 20 μg of protein 
total cell extract were analysed by Western blot analyses with, mTOR, RAPTOR, PRAS40 
Rictor and phosphorylated (Thr389) p-p70S6K. Signal was detected using peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibodies (Jackson Immunoresearch Labs, 
Inc., Baltimore, USA). The enhanced chemi-luminescence (ECL) system (Amersham) was 
used for detection and image detection was performed with UVITEC Alliance 4.7 system 
(Cambridge, UK). To control the amount of proteins in total cell lysate transferred to 
nitrocellulose membrane β-actin was used and detected by anti β-actin mAb (clone AC-15, 
Sigma, St. Louis, USA). 
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3.9 Detection and analysis of soluble factor 
 
1x106 HFF, HF, BJ and EA.hy926 cells were plated into 150mm dishes (Falcon BD). After 
24 hours from the plating, the culture medium was replaced by SFM, and after 24 hours, 
media were collected and cells were counted. Cells culture media were analysed by 
Proteome Profiler (Antibody Arrays, R&D System) according to the manufacturer's 
protocol.  
X-MAN™ isogenic HCT116 cell lines cell culture media were analysed in triplicate as per 
the manufacturer’s instructions using IL-8, IL-6 and MCP-1 specific ELISA, purchased 
from ENZO Life for IL-8 and IL-6 analysis and from R&D Systems for MCP-1 analysis. 
Absorbance was read at 450 nm.  IL-8, IL-6 and VEGF expression was represented as 
pg/mL and then related to the control. 
Recombinant human CXCL8/IL-8 and IL-6 were purchased from R&D System. For 
recombinant protein experiment 500 pg/mL of IL-8 and 1000 pg/mL of IL-6 were used in 
DMEM medium without the addition of FBS. 
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4 Results 
 
4.1 Response to MEK inhibition is dictated by CRC genetic background 
 
To investigate the role of PTEN in modulating the response of CRC cells to MEK 
inhibition (trametinib, MEKi), X-MAN™ isogenic HCT116 cell lines (HCT116 and 
HCT116 PTEN-/-) were treated with increasing concentrations of the MEK inhibitor 
trametinib (1-1000 nM) for 72 hours, in different culture conditions: isogenic HCT116 
cells grown in SFM, isogenic HCT116 cells grown in the presence of HFF CM and 
isogenic HCT116 cells co-cultured with GFP-tagged fibroblasts (HFF). Effects on cell 
growth/viability were monitored by Crystal Violet Assay.  
In order to evaluate the influence that microenvironment could exert in modulating 
response to treatment, the contribution of direct cell-to-cell contact and soluble factors 
produced by fibroblast cell was evaluated using co-culture and fibroblast CM experiments.  
The functional effects of MEKi on viability and cell growth is shown in Figure 3: 
regardless of cell culture conditions (isolated tumor cells, HFF CM, or HFF co-culture), the 
parental HCT116 cell line (PTEN-competent) was significantly more sensitive to MEK 
inhibition, as compared to its PTEN-loss counterpart (HCT116 PTEN-/-). IC50 was less than 
1 nM in parental HCT116 under any culture condition, while it increased to 6 nM, 68 nM, 
and 215 nM in HCT116 PTEN-/-, under HFF co-culture, isolated culture, and HFF CM 
culture conditions, respectively. 
 
 
 
Figure 3. PTEN influences the response to MEKi independently from microenvironmental elements. 
Cells were treated with increasing concentration of drugs, as indicated for 72 hours. Effects on cell growth 
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were monitored by Cristal Violet assay for both SFM (w.o. FBS, A) and CM (HFF CM, B) conditions and by 
cytofluorimetric analysis for Co-culture (C). The percentage of viability was represented as % of control, 
assuming the levels in control cells as 100%. Results represent the average +SD of three independent 
experiments. Asterisks indicate statistically significant differences (p <0.01 by 2-tailed Student’s t test) for 
the comparison between * HCT116 and HCT116 PTEN-/- treated with MEKi. 
 
 
4.2 Response to PI3K/mTOR double inhibition is modulated by CRC/TME 
interactions 
 
To investigate the role of PTEN status in modulating the response to PI3K/mTORi 
(gedatolisib), the same analysis was performed for PI3K/mTORi (at concentration ranging 
from 1 to 1000 nM for SFM and CM condition and from 1 to 100 nM for co-culture 
experiments). As opposed to MEKi treatment, the presence of stromal elements strongly 
influenced the response to PI3K/mTORi. As shown in Figure 4, response of isogenic 
HCT116 cell lines to PI3K/mTORi was independent of PTEN status (IC50 for both 
HCT116 and HCT116 PTEN-/-: 13.65 nM). However, sensitivity of parental HCT116 cells 
(PTEN-competent) to the growth inhibitory activity of PI3K/mTORi was significantly 
increased in the presence of fibroblast CM (IC50: <1), while was not modulated in the 
HCT116 PTEN-/- cell line (IC50: 11.96). Conversely, direct cell-to-cell contact in a co-
culture setting, rendered both HCT116 and HCT116 PTEN-/- more resistant to 
PI3K/mTORi treatment (IC50: 83.90 and 322.04, respectively). 
 
 
 
Figure 4. The PI3K/mTOR double inhibitor response is strongly influenced by microenvironmental 
soluble factors in PTEN competent cells. HCT116 and HCT116 PTEN-/- cells were treated with increasing 
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concentration of drugs, as indicated for 72 hours. Effects on cell growth were monitored by Cristal Violet 
assay for SFM (w.o. FBS, A) and CM (HFF CM, B) conditions and by cytofluorimetric analysis for Co-
Culture (C). The percentage of viability was represented as % of control, assuming the levels in control cells 
as 100%. Results represent the average +SD of three independent experiments. Asterisks indicate statistically 
significant differences (p <0.01 by 2-tailed Student’s t test) for the comparison between * HCT116 and 
HCT116 PTEN-/- treated with PI3K/mTORi. 
 
 
4.3 Pharmacologic interactions between MEK and PI3K/mTOR inhibitors are 
profoundly modulated by CRC/TME interactions 
 
We further tested pharmacologic interactions between MEKi and PI3K/mTORi, using a 
fixed dose-ratio (1:1) experimental design over a wide range of concentrations (1–1000 
nM) of each agent, under the culture conditions described above: isogenic HCT116 cells 
grown in SFM and isogenic HCT116 cells co-cultured with GFP-tagged fibroblasts (HFF). 
Figure 5 shows that under SFM culture conditions pharmacologic interactions between the 
two agents were strongly synergistic in HCT116 PTEN-/- cells (CI: 0.530) and antagonistic 
in PTEN-competent HCT116 cells (CI: 23.089), as previously described in FBS-
supplemented culture conditions [76].  
While the presence of soluble factors in HFF CM did not substantially modify 
pharmacologic interactions between MEKi and PI3K/mTORi in either cellular model 
(synergistic in HCT116 PTEN-/-: CI 0.301; additive in HCT116: CI 1), direct cell-to-cell 
completely subverted the type of interaction: indeed, under co-culture conditions, 
combined MEKi and PI3K/mTORi treatment became additive in HCT116 PTEN-/- (CI: 
0.993) and strongly synergistic in parental HCT116 (CI: 0.001).  
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Figure 5. Effect of combined MEKi and PI3K/mTORi in isogenic CRC cell lines. HCT116 (top panel) 
and HCT116 PTEN-/- (bottom panel) cells were exposed to MEKi and PI3K/mTORi in a fixed dose-ratio 
combination (1:1) in SFM (w.o. FBS), with CM (HFF CM) and Co-culture (Co-Culture). CI were calculated 
by conservative isobologram analysis for experimental data and plotted against the fraction affected. 
 
 
4.4 Exposure to fibroblast CM selectively increases sensitivity of PTEN-competent 
HCT116 cells to double PI3K/mTOR inhibition 
 
Among drug response-modulating effects of CRC/TME interactions, sensitization of 
PTEN-competent cells to the growth inhibitory action of PI3K/mTOR double inhibitor in 
the presence of HFF CM was one of the most prominent; in order to investigate which 
signalling hub along the PI3K cascade was responsible of the observed effect, we 
investigated the functional effects of different molecular target inhibitors (Figure 6) on cell 
viability under SFM and CM culture conditions. 
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Figure 6. PI3K/AKT/mTOR pathway inhibitors. (Ciuffreda L.) 
 
 
X-MAN™ HCT116 and HCT116 PTEN-/- cell lines were exposed to increasing 
concentration of alpelisib (selective class I PI3K inhibitor, 5-5000 nM), MK-2206 
(allosteric AKT inhibitor, 10-1000 nM) and everolimus (rapamycin-like mTORC1 
inhibitor, 1-1000 nM) for 72 hours in SFM or HFF CM.  
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As shown in Figure 7, selective inhibition of a single step along the PI3K pathway was not 
sufficient to result in drug sensitization in the presence of HFF CM. Indeed, no differences 
were observed in the response of either HCT116 or HCT116 PTEN-/- to class I PI3Ki, 
AKTi, and mTORC1i in the presence of HFF CM, as compared to SFM, suggesting that 
exposure to fibroblast CM selectively increases the sensitivity of PTEN-competent 
HCT116 cells to double PI3K/mTOR inhibition. 
 
 
 
Figure 7. Effect of different PI3K pathway inhibitors in response in isogenic colorectal cancer cell 
lines. Isogenic colorectal cancer cell lines HCT116 and HCT116 PTEN-/- were treated with increasing 
concentration of drugs, as indicated, in both SFM and HFF CM. The percentage of viability was represented 
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as % of control, assuming the levels in control cells as 100%. Results represent the average +SD of three 
independent experiments. Asterisks indicate statistically significant differences (p <0.01 by 2-tailed Student’s 
t test) for the comparison between * SFM and HFF CM condition. 
 
 
4.5 Soluble factors released in fibroblast CM modulate PTEN function  
 
Since the PI3K/mTORi-sensitizing effect of fibroblast CM was selectively observed in 
PTEN-competent CRC cells, we set out to investigate whether CM influenced PTEN 
expression and function. Thus, we investigated PTEN expression and function in response 
to fibroblast CM in parental HCT116 cells.  
Western blot analysis, shown in Figure 8, shows that PTEN expression was upregulated 
with HFF CM until 48 hours and SFM was used as control to calculate the variations of 
proteins expression levels as compared to HFF CM. 
These results correlate with increased levels of p-PTEN Ser380/382/383 C-tail 
phosphorylation in the presence of HFF CM.  It is currently known that phosphorylation of 
PTEN C-tail results in an hyperactivation of PI3K pathway; moreover, this post-
translational modification does not allow the protein to bind the plasmatic membrane thus 
interfering with its localization, stability and activity [78, 79].  Consistently, our results 
showed that the upregulation of PTEN C-tail phosphorylation is associated with an 
increased level of p-p70S6K Thr389, suggesting an activation of PI3K pathway related to 
HFF CM.  
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Figure 8. The CM upregulates total PTEN and PTEN C-tail phosphorylation. HCT116 cells were 
cultured with SFM (w.o FBS) and fibroblast CM (HFF CM). After 24 and 48, HCT116 cells were lysed and 
analysed by Wester Blotting using the indicated antibodies and -actin was used as protein loading and 
blotting control. 
 
 
In order to understand how PTEN was distributed in the cell in presence of HFF CM, we 
investigated PTEN subcellular localization as compared to SFM using 
immunofluorescence analysis. 
HCT116 and HCT116 PTEN-/- were seeded on coverslips and the media was replaced by 
SFM and HFF CM after 24 hours from plating; specific antibody for PTEN was incubated 
overnight to detect its distribution. 
As shown in Figure 9, immunofluorescence experiments revealed that HFF CM 
upregulated PTEN expression and was associated with a diffuse, cytoplasmic distribution 
of tumour suppressor in the cells.  
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Figure 9. Fibroblast CM upregulates PTEN expression and a spread distribution of PTEN. Isogenic 
CRC cells were exposed to different cell culture condition: SFM (w.o FBS), fibroblast CM (HFF CM) and 
complete medium (RPMI+FBS), for 24 h; PTEN levels was then assessed by Immunofluorescence using 
specific antibodies. Microphotographs were taken at ×63 magnification. Results from one experiment 
representative of at least three independent experiments performed with superimposable results are shown. 
Immunofluorescence of PTEN in HCT116 PTEN-/- is shown as PTEN negative control. 
 
 
Further check the functional status of PTEN phosphatase activity, we also detected the 
main PTEN substrate, the phospholipid second messenger PIP3, which is dephosphorylated 
by PTEN to yield PIP2. PIP3 and PTEN protein levels and localization were analysed by 
Immunofluorescence assay in SFM and HFF CM (Figure 10). Protein detection showed an 
increase in PIP3 levels using HFF CM. Moreover, as shown in merge images, PTEN and 
PIP3 did not co-localize. 
 
 
 
Figure 10. The CM leading to PTEN partial inactivation. HCT116 cells were cultured in SFM (w.o. FBS) 
and HFF CM for 24 h. PTEN and PIP3 levels were then assessed by Immunofluorescence using specific 
antibodies. Microphotographs were taken at ×63 magnification. Results from one experiment representative 
of at least three independent experiments performed with superimposable results are shown. 
 
 
These data underline that soluble factors derived from fibroblast cells decreased PTEN 
phosphatase activity leading to PI3K pathway basal activation. 
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4.6 Soluble factors released by stromal cells activate the mTORC1 complex and 
increase sensitivity to PI3K/mTORi treatment 
 
In order to understand whether PI3K pathway activation downstream of PTEN in response 
to fibroblast CM would result in a shift of the balance between mTORC1 and mTORC2 
complexes, mTOR immunoprecipitation experiments were carried out in isogenic 
colorectal cancer cells in both SFM and HFF CM conditions.  
As shown in Figure 11, IP/WB experiments revealed that exposure of parental HCT116 
cells (PTEN-competent) to fibroblast CM induced the association of mTOR with Raptor 
and the release of PRAS40 from the complex, while no difference in Rictor association 
with mTOR was observed in different culture conditions. Conversely, in the absence of 
PTEN (HCT116 PTEN-/-) no significant changes in mTOR complexes’ composition was 
observed. These results suggest specific activation of the mTORC1 complex in response to 
fibroblast CM in PTEN-competent CRC cells, which, in turn, resulted in downstream 
pathway activation, as demonstrated by p-p70S6K Thr389 phosphorylation in parental 
HCT116, but not HCT116 PTEN-/-.  
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Figure 11. HFF CM activates PI3K/mTOR pathway in PTEN-wt context leading to mTORC1, but not 
mTORC2, complex activation. Isogenic CRC cells were subjected to SFM and HFF CM culture condition 
for 24 h; Endogenous mTOR was immunoprecipitated and the immunocomplexes were blotted for RAPTOR, 
PRAS40 and Rictor. RAPTOR, PRAS40, Rictor and p-p70S6K Thr389 levels in total cell lysates are also 
shown. GAPDH was used as protein loading and blotting control in total cell lysate. 
 
 
We then investigated the molecular effects of PI3K/mTOR double inhibitor in HCT116 
and HCT116 PTEN-/- cell lines under different culture conditions. Cell lines were exposed 
to increasing concentration of the drug for 24 hours in SFM and in the presence of HFF 
CM (Figure 12). As expected from the formation and activation of the mTORC1 complex 
described above, exposure of HCT116 to fibroblast CM increased p-4E-BP1 Thr37/46 and 
p-p70S6K Thr389 levels, which were more effectively suppressed by PI3K/mTORi 
 29 
 
treatment in parental HCT116 cells. No differences between SFM and HFF CM conditions 
were observed in the HCT116 PTEN-/- cell line, in which PI3K/mTORi treatment proved 
to be equally efficient in shutting down 4E-BP1 and p70S6K phosphorylation in both culture 
conditions (data not shown). 
Exposure to fibroblast CM slightly increased basal p-ERK levels, but those were not 
modulated by PI3K/mTORi, independent of PTEN status. 
 
 
 
Figure 12. The CM increases the HCT116 response to PI3K/mTORi. HCT116 cells were incubated with 
increasing doses of PI3K/mTORi, as indicated, for 24 hours SFM and HFF CM. Protein lysate was analysed 
by Western Blotting using p-ERK, p-4E-BP1 and p-p70S6K specific antibodies. -Actin was used as protein 
loading and blotting control. 
 
 
4.7 Stromal cell CM upregulates PI3K pathway and PI3K/mTOR double inhibitor 
response 
 
We next investigated the effects of CM derived from different stromal cells on 
PI3K/mTOR activation and response to the PI3K/mTOR double inhibitor gedatolisib in 
isogenic CRC cell lines. To this purpose, HCT116 and HCT116 PTEN-/- were exposed to 
SFM and CM derived from normal fibroblast cell lines (BJ and HF) or endothelial cells 
(EA.hy926).  
As shown in Figure 13, p-4E-BP1 Thr37/46 and p-p70S6K Thr389 levels in SFM and with 
stromal CM derived from HFF, BJ, HF and EA.hy926 were detected using Western blot 
analysis.  Even in this case, p-ERK Thr202/Tyr204 protein levels were analysed as control 
of the analysed system.  
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Figure 13. Stromal soluble factors upregulate PI3K pathway in PTEN competent tumor cells. Isogenic 
CRC (HCT116 top panel and HCT116 PTEN-/- bottom panel) cells were cultured with SFM and stromal cells 
CM, as indicated, for 24h. Protein lysate was analysed by Western Blotting using p-ERK, p-4E-BP1 and p-
p70S6K specific antibodies. -Actin is used as protein loading at blotting control. SFM was used as control for 
calculate system variations. 
 
 
As already observed with HFF CM, p-4E-BP1 Thr37/46 and p-p70S6K Thr389 levels were 
upregulated with all stromal cell CM in PTEN-competent parental HCT116 cells, whereas 
no striking differences were observed in HCT116 PTEN-/-. Conversely, p-ERK 
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Thr202/Tyr204 levels were slightly increased by exposure to stromal cell CM, regardless 
of PTEN status. 
Overall, these results support the hypothesis that PTEN mediates paradoxical PI3K 
pathway activation in response to soluble factors released in the TME by stromal elements 
(fibroblasts, endothelial cells). 
We further verified that PI3K/mTOR activation in response to different stromal cell CM 
would result in increased sensitivity to PI3K/mTORi in PTEN-competent CRC cells. To 
this purpose, HCT116 and HCT116 PTEN-/- were exposed to two different concentrations 
of PI3K/mTORi (1 and 10 nM) for 72 hours in SFM and stromal cell CM (Figure 14).  
Regardless of the stromal cell used as the source of CM, CM selectively increased 
sensitivity to PI3K/mTORi in parental HCT116. In particular, fibroblast-derived CM had 
greater influence on response to PI3K/mTORi, as compared to endothelial cell-derived 
CM. Conversely, HCT116 PTEN-/- did not respond to PI3K/mTORi, regardless of the 
source of CM.  
 
 
 
Figure 14. Analysis of stromal-induced response to PI3K/mTORi treatment.  XMAN isogenic HCT116 
cells were treated with increasing concentration of PI3K/mTORi, as indicated, for 72h in SFM and stromal 
CM. Effects on cell growth were monitored by Crystal Violet assay. The percentage of viability was 
represented as % of control, assuming the levels in control cells as 100%. Results represent the average +SD 
of three independent experiments. Asterisks indicate statistically significant differences (**: p <0.01 or *: p < 
0.05 by 2-tailed Student’s t test) for the comparison between SFM and stromal cells CM response. 
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4.8 Screening of cytokines and chemokines production by stromal cells  
 
To preliminarily ascertain which soluble factors produced by stromal cells could be 
candidate mediators of the PI3K/mTOR pathway activation and, most importantly, of the 
PI3K/mTORi-sensitizing effects, CM from different fibroblasts (HFF, BJ and HF) and 
endothelial cells (EA.hy926) were analysed by Proteome Profiler Array after 24 hours of 
culture in SFM (Figure 15). 
 
 
 
Figure 15. Analysis of cytokine/chemokine production by stromal cells reveals similar patterns of 
expression. Cell culture media of HFF, BJ, HF and EA.hy926  were analysed by Proteome Profiler Array. 
 
 
As shown in Table 1, different cell lines of fibroblast and endothelial cells produce a 
similar pattern of cytokines and chemokines expression. Some of them are commonly 
produced by both fibroblast and endothelial cells (e.g.  IL-8, IL-6, UPAR), while other 
were relatively specific for fibroblasts (e.g. MCP-1, SDF-1 and Angiopoietin-1). 
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Table 1. Profiling proteins in stromal cells CM 
 
 
We also confirmed the presence of some of the detected cytokines by ELISA. As shown in 
Figure 16, IL-8 was produced at variable levels by all stromal cells tested; IL-6 was 
produced by fibroblasts and at very low levels by endothelial cells, while MCP-1 was 
selectively produced by fibroblasts. 
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Figure 16. IL-8, IL-6, and MCP-1 expression in stromal cells. Stromal cells, were analysed by ELISA 
assay; the results are expressed as pg/mL.  
 
 
To assess the potential role of two of the main soluble factors detected in stromal cell CM 
(IL-8 and IL-6), we tested the molecular effect of recombinant human IL-8 and IL-6, alone 
and in combination, when added to SFM. The concentration of recombinant proteins was 
chosen based on the levels of cytokine detected by ELISA assay in CM (500 pg/mL for IL-
8 and 1000 pg/mL for IL-6).  
As shown in Figure 17, both cytokines stimulated ERK phosphorylation at Th202/Tyr204, 
and to a lesser extent of 4E-BP1 Thr37/46, in parental HCT116 cells; conversely, 
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phosphorylation of p70S6K at Thr389 was selectively induced by HFF CM, while 
recombinant IL-8 and IL-6, either alone or in combination, were not able to induce 
mTORC1 activation.  
 
 
 
Figure 17.  IL-8 and IL-6 do not mediate mTORC1 activation in the HFF CM. HCT116 cells were 
cultured with SFM, HFF cells CM, and SFM with recombinant Human protein of IL8, IL6 and the 
combination of two (500pg/ml, 1000pg/ml and 500pg/ml+1000pg/ml, respectively) as indicated, for 24h. 
Protein lysate was analysed by Western Blotting using p-ERK, p-4E-BP1 and p-p70S6K specific antibodies. -
Actin is used as protein loading at blotting control. SFM was used as control for calculate system variations. 
 
 
These data underline that a similar profile of cytokine/chemokines was secreted by 
different stromal cells: IL-8 and IL-6 were produced, albeit at variable levels, by all 
fibroblast cells, but were not able to mediate mTORC1 activation in PTEN-competent 
CRC cells. 
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5 Discussion and conclusions 
 
Recent advances in high-throughput technologies are responsible of the carachterization of 
numerous genes in different human cancers. Increased knowledge of cancer mutations, 
allowed not only to understand the evolution of the tumour in its various steps, but also to 
the development of personalized therapies for patients [80]. Indeed, prognostic and 
predictive biomarkers have been identified in several cancers, including CRC; for example, 
only patients lacking KRAS or NRAS mutations could benefit from cetuximab and 
panitumumab treatment [81]. 
The present study provides evidence that PTEN expression could influence the response to 
targeted therapies in the presence of stromal and microenvironmental elements. 
We recently demonstrated that the lack of PTEN is a crucial determinant of synergistic 
interactions between MAPK and PI3K inhibitors in a panel of cancer cells of different 
histological origins [76]. Furthermore, several recent studies indicate that PTEN status 
influence tumour growth, survival, invasion, angiogenesis and metastasis in different 
tumour or surrounding cells, for example through the production of cytokine and 
chemokine [82, 83]. Indeed, recent data obtained in our lab indicate a correlation between 
the occurrence of BRAFV600E mutations and/or PTEN-loss and higher levels of IL-8 
production in CRC cells [84]. Whether it occurs through the production of soluble factors 
or through direct cell-to-cell contact, it is currently recognized that TME plays a pivotal 
role in cancer progression and metastasis, but it also has a profound effect on therapeutic 
efficacy [75]. Bidirectional communication between tumour cells and their 
microenvironment is critical at different stages of tumour development and progression 
and the capability of stromal cells to modify the TME can exhibit opposite effects: tumour-
promoting or tumoricidal capacities. Moreover, the importance of stromal elements led to a 
new, microenvironment-based CRC classification, developed in datasets obtained by 
profiling whole-tumour samples containing both tumour and stromal cells; this 
classification is composed by four different subtypes, in order to correlate each subtype 
with patient outcome [85]. 
CAFs represent one of the most abundant stromal cell types in several cancers and, at a 
difference from epithelial tumor cells, mutations and loss of heterozygosity are rare; recent 
evidence are actually focused on defining a "CAF signature", indeed, depending on stimuli 
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received by cancer cells, CAFs could exert suppressive or stimulatory effects in response 
to TME [86, 87]. 
Based on this evidence we set up multicellular culture models to study the interplay 
between the tumor genetic background (namely PTEN-inactivating events) and the 
surrounding TME and elucidate the molecular mechanisms of interactions, with specific 
regard to the growth-inhibitory effects of potentially therapeutic signalling inhibitors. 
From preliminary data, we observed that the presence or absence of serum in culture 
medium induces profound changes in the phosphoproteome profile, upregulating different 
signalling pathways. Thus, in order to standardize basal levels of pathway activation, we 
set up isolated CRC cell cultures, CM, and co-culture experiments in SFM. We 
investigated the response to MEKi, PI3K/mTORi and their combination in isogenic CRC 
cell lines, that only differ for PTEN status, under different conditions of growth (SFM, 
fibroblast CM and co-culture). The results obtained show that response to MEKi was 
independent from the presence of microenvironmental elements (Figure 3). Conversely, the 
impact of PI3K pathway inhibitors on stromal elements has been recently studied and the 
potential anti-tumor efficacy of their inhibition may also derive from interference with the 
capability of tumour cells to respond to different stromal signals, thus underpinning cell-
specific roles of the PI3K/mTOR pathway both in cancer cells and in the tumor 
microenvironment [88]. At a difference from MEKi, in our system the presence of 
fibroblast-derived soluble factors strongly and selectively increased the response of PTEN-
competent CRC cells (HCT116) to the PI3K/mTOR double inhibitor gedatolisib (Figure 
4). As opposed to the results obtained in isolated tumor cell cultures [76], response to 
combined MEKi/PI3Ki treatment was dramatically changed by direct cell-to-cell contact 
between CRC cells and stromal fibroblasts (Figure 5): indeed, combination treatment in 
co-culture results in synergistic effects only in PTEN-competent cell line. 
The signalling hub at which PI3K pathway inhibition takes place appears to be relevant: 
indeed, fibroblast CM-mediated drug-sensitizing effects were only observed with double 
PI3K/mTOR inhibition, whereas response to different single-step PI3K pathway inhibitors 
were not influenced by fibroblast-derived soluble factors (Figure 7). The first generation of 
PI3K pathway inhibitors (i.e wortmannin and LY294002), were associated with elevated 
toxicity and a limited therapeutic efficacy; increased interest, however, has grown over the 
years for PI3K/mTOR double inhibitors. BEZ235, GSK2126458, gedatolisib, apitolisib 
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and PQR309, have an apparently greater antitumor activity, although safety and tolerability 
remain of some concern [89]. Experiments conducted in spheroid models and transgenic 
mice suggest that dual PI3K/mTOR inhibition is a potential treatment strategy for APC- 
and PI3K-mutant colorectal cancers [90]; our data add to such evidence, indicating that 
PTEN-competent CRC cells might respond best to PI3K/mTOR double inhibition in the 
presence of microenvironmental cues, mediated by soluble factors. 
Biallelic inactivation of PTEN occurs in 20-30% of case of CRC and is currently known 
that PTEN alterations and MSI are correlated [91]. However, the evaluation of PTEN 
functional state is cumbersome and requires expression and function analysis, in addition 
to sequencing of the entire gene; this is due to the fact that PTEN function is finely 
regulated through the control of its expression, through genetic and epigenetic 
mechanisms, post-translational modifications or changes in its subcellular localization 
[92]. Moreover, PTEN tumour suppressor function is not just limited to its lipid 
phosphatase activity: its multiple role, indeed, has recently been expanded to include 
different subcellular location where it performs distinct functions, such as in the nucleus, 
where it favours genomic stability and controls cell cycle progression, in the endoplasmic 
reticulum (ER) and mitochondria-associated membranes (MAMs), where PTEN interacts 
with the inositol 1,4,5-trisphosphate receptors (IP3Rs) and regulates the sensitivity to 
apoptosis [93].  
Since the drug sensitizing effects of fibroblast CM were observed only in cells that express 
a functional PTEN protein, we analysed the effects of CM on PTEN expression and 
function. Despite increased PTEN protein levels, PTEN phosphorylation at 
Ser380/382/383 was increased, thus explaining the paradoxical functional inactivation of 
the PTEN tumour suppressor (Figure 8). Consistent with the key role of C-tail 
phosphorylation in determining an alteration of PTEN to an inactive state, resulting in a 
reduction of phosphatase activity and a lower association of plasmatic membrane 
association [94], immunofluorescence and WB experiments showed an apparently 
paradoxical response to CM stimulation: indeed, PTEN protein levels were increased upon 
CM stimulation, but its distribution within the cell became spread in the cytoplasm, instead 
of membrane-associated (Figure 9); indeed, PIP3 levels were increased upon CM 
stimulation and did not co-localize with PTEN (Figure 10), resulting in overall 
downstream pathway activation, as demonstrated by the upregulation of p-p70S6K Thr389. 
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Activation of the mTOR pathway has been described in intestinal polyp formation and 
mTORC1 activation, in particular, appears to be involved in both tumour initiation and 
progression in CRC, enhancing CIN levels [95]. Results presented here show that exposure 
to fibroblast CM shifts the balance towards mTORC1 activation, by stimulating the 
association of RAPTOR, but not PRAS40, with mTOR selectively in PTEN-competent 
contexts; conversely, mTORC1 and mTORC2 did not differ in HCT116 PTEN-/-, 
regardless of CM stimulation (Figure 11). Moreover, in PTEN-competent CRC cells, 
activation of the mTORC1 complex was associated with a sustained response to 
PI3K/mTOR double inhibition (Figure 12). These results are consistent with evidence that 
cells over-expressing p-p70S6K and p-4E-BP1 were more sensitive to PI3K/mTOR inhibitor 
treatment [96]. Functional interaction between tumor genetic background (PTEN status) 
and microenvironmental cues (soluble factors released in CM) specifically controls 
activation of the PI3K/mTOR pathway, while the MAPK pathway is upregulated in the 
presence of HFF CM independently of PTEN status. We previously demonstrated that 
constitutive ERK activation represses PTEN expression in melanoma and other cancer 
models, through c-Jun and miR-25 [97]; however, c-JUN and miR-25 were not modulated 
by HFF CM in parental HCT116 (data not shown).  
It is becoming increasingly evident that TME is composed by a heterogeneous mixture of 
tumour cells plus endogenous stroma that differ for soluble factors production that 
influence not only homing, invasion and migration of tumour cells but also mechanisms of 
sensitivity/resistance to drug [98]. We thus analysed fibroblasts from different sources and 
endothelial cells, for their ability to produce soluble factors that would modulate PI3K 
pathway activation and sensitivity to PI3K/mTOR double inhibition. Effects observed with 
HFF CM were confirmed with different stromal cells; however, endothelial cells were less 
effective in increasing the response to PI3K/mTOR double inhibitor. The analysis of 
cytokine/chemokine production revealed a similar pattern in CM from different stromal 
cells (Table 1). However, although IL-8 and IL-6 were among the most prominent 
common factors produced by all stromal cells, molecular data revealed their relative 
inability to induce mTORC1 activation in PTEN-competent HCT116 cells (Figure 17).  
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6 Future prospects 
 
Overall, the work conducted so far demonstrates that in a preclinical model of CRC: 1) 
sensitivity to MAPKi is dictated mostly by the tumor genetic background (PTEN status), 
while sensitivity to PI3K/mTOR inhibition and pharmacologic interactions with combined 
MAPK/PI3K inhibition is strongly influenced by interaction with the TME; 2) in PTEN-
competent cells soluble factors released by stromal elements paradoxically impair PTEN 
function, leading to downstream mTORC1 complex formation and pathway activation; 3) 
paradoxical mTORC1 activation upon exposure to stroma-derived soluble factors results in 
functional hypersensitivity of PTEN-competent CRC cells to the growth inhibitory effects 
of double PI3K/mTOR inhibitors.  
We recognize the fact that using immortalized fibroblasts to model tumor/stroma 
interactions represents a gross oversimplification of the in vivo situation and does not 
entirely reflect the real cancer tissue and TME. As a first step towards creating more 
physiological multicellular preclinical models, we are currently isolating autologous 
fibroblasts and cancer cells from patients affected by CRC at different stages. 
Nevertheless, our data provide solid evidence that factors contained in fibroblasts’ CM 
may trigger paradoxical mTORC1 activation, selectively in the presence of a functional 
PTEN protein. Regardless of the identification of the specific factor responsible for this 
effect, paradoxical PI3K/mTOR activation in a PTEN-competent context, may represent a 
novel therapeutic target, potentially amenable to pharmacological intervention (e.g. by 
PI3K/mTOR kinase inhibitors, as highlighted here).  
We are also aware that many other factors, in addition to cytokines and chemokines, may 
influence the interactions between the tumor and its TME. Recent evidence show that 
communication between tumor and stromal cells can be also mediated by miRNAs [99] 
and numerous miRNAs have been identified in PTEN regulation in tumors of different 
histological origins [100, 101]. For this reason, to evaluate the putative role of miRNAs in 
stromal CM, we will isolate extracellular miRNA derived from stromal CM [102]. miRNA 
analysis will be carried out also through the isolation of exoRNA; indeed, exosomes are 
cell derived vescicles abundant in biological fluids, and miRNAs or RNA inside could be 
isolated using specific ultracentrifugation and analyzed to identify possible mediators of 
PTEN inactivation. 
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